Luc Barraud

Head of Assays and Imaging Lab - Transgene

[Transgene @TransgeneSA]

.@TransgeneSA launches Invir.IO, integrated platform for the next generation of multifunctional #OncolyticViruses https://t.co/A4VSxUP329

[Transgene @TransgeneSA]

Rencontrez aussi .@TransgeneSA et C Ancel sur l'organisation de la sous-traitance de production et de contrôle ;-) https://t.co/UCRAMMvVYd

[CurieCancer @CurieCancer]

@institut_curie is proud to be part of this exciting study with @TransgeneSA cc @chletourneau https://t.co/2OGxv6SBXn

[Transgene @TransgeneSA]

1st patient treated with TG4001+ avelumab @institut_curie in Ph.1/2 trial against HPV+ cancers @merckgroup @pfizer https://t.co/XMOrXKpygA

[HISTALIM @HISTALIM]

Tumor immunoprofiling: @HISTALIM launches HISTOPROFILE https://t.co/X0WN7Gs4Cm #AACR17 #MultiplexIHC #ImmunoOncology @AACR #AACR #AACR2017

[ESTBB de Lyon @ESTBB_Lyon]

Emmanuelle Gormally @ESTBB_Lyon au colloque Global Biobank Week 2017 à Stockholm #GBWstockholm #biobanking

[BiotechFinances, Medtech, Santé Numérique, DTx, IA @Biotech_finance]

Le pipe de Transgene en clair... https://t.co/1Zvl7gwXTl

[Transgene @TransgeneSA]

@TransgeneSA reports H1 results in line with objectives: all clinical programs progressing & new collaborations https://t.co/XmcjHP18Kr

[MEDiSTRAVA, an Inizio Company @MEDiSTRAVA_]

CLIENT NEWS: @TransgeneSA receives IND approval to begin trial with #TG4010 + #nivolumab + chemo in 1st line #NSCLC https://t.co/X8mrduhfy6

[Natixis Research CIB @NatixisResearch]

Découvrez l’éclairage de notre spécialiste #biotech sur la nouvelle approche révolutionnaire pour traiter le cancer via @TransgeneSA ⤵️ https://t.co/okjeRArD0m

[Transgene @TransgeneSA]

.@TransgeneSA on @euronews "Using viruses to fight cancer", also with JJ Le Fur from @NatixisResearch https://t.co/XuKZm3ijrW

[Transgene @TransgeneSA]

@TransgeneSA and @BERGONIE33 Present a Poster on the METROmaJX Trial at #ESMO17 #Pexa-Vec #OncolyticVirus https://t.co/bx7OQ29X1J

[Luc Barraud @LucBarraud]

Antibody Therapeutics Hinder Immune Evasion https://t.co/sIa9Vq3VfG via @genbio

[Transgene @TransgeneSA]

"Virus against cancer", interesting article on the German site of @themotleyfool#Pexa-Vec https://t.co/OrmiEaylc4

[Transgene @TransgeneSA]

1st patient treated in clinical trial combining oncolytic virus Pexa-Vec with nivolumab in liver cancer https://t.co/SBmw1RtIlF

[Transgene @TransgeneSA]

Article sur .@TransgeneSA paru ce week-end dans l'édition abonnés d' @InvestirFr https://t.co/roNxHaMvhI

[MEDiSTRAVA, an Inizio Company @MEDiSTRAVA_]

CLIENT NEWS: @TransgeneSA announces Cancer Research publication confirming the potential of next generation OV https://t.co/oKkHeTzVnd

[Transgene @TransgeneSA]

New publication in Cancer Research. Local and absocopal effects demonstrated with new generation of #OncolyticVirus. https://t.co/Q8RUNYUJ1Z

[Edison @Edison_Inv_Res]

Outlook on @TransgeneSA: Building a strong immunotherapy portfolio. https://t.co/JdNIyiUQ9O 11 CTs over next 12-18 months, data this yr $TNG